UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 10, 2004

CELLEGY PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Its Charter)

California

(State or Other Jurisdiction of Incorporation)

0-26372		82-0429727
(Commission File Number)		(IRS Employer Identification No.)

349 Oyster Point Boulevard, Suite 200 South San Francisco, CA		94080
(Address of Principal Executive Offices)		(Zip Code)

(650) 616-2200
(The Registrant’s Telephone Number, Including Area Code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

99.1 Press Release, dated August 10, 2004, reporting the results of operations of Cellegy Pharmaceuticals, Inc. (the “Registrant”) for its second quarter ended June 30, 2004 (furnished and not filed herewith solely pursuant to Item 12).

Item 12. Results of Operations and Financial Condition

On August 10, 2004, the Registrant reported its results of operations for its second quarter ended June 30, 2004. A copy of the press release issued by the Registrant concerning the foregoing results is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CELLEGY PHARMACEUTICALS, INC.


Dated: August 10, 2004		By:	/s/ A. Richard Juelis
		Name:	A. Richard Juelis
		Title:	Vice President, Finance and Chief Financial Officer

EXHIBIT INDEX

Exhibit Number		Description of Document

99.1		Press Release of Registrant, dated August 10, 2004, reporting the results of operations for the Registrant’s second quarter ended June 30, 2004.